Showing results 1 to 1 of 1
| Title | Author(s) | Issue Date | |
|---|---|---|---|
Garadacimab for hereditary angioedema prophylaxis: Long-term efficacy and safety from the VANGUARD Phase 3b open-label extension trial (first interim analysis) Proceeding/Conference:13th C1-inhibitor Deficiency & Angioedema Workshop | 2023 |